218 related articles for article (PubMed ID: 28266890)
1. Examination of the Phenomenology of the Ibogaine Treatment Experience: Role of Altered States of Consciousness and Psychedelic Experiences.
Heink A; Katsikas S; Lange-Altman T
J Psychoactive Drugs; 2017; 49(3):201-208. PubMed ID: 28266890
[TBL] [Abstract][Full Text] [Related]
2. The ibogaine medical subculture.
Alper KR; Lotsof HS; Kaplan CD
J Ethnopharmacol; 2008 Jan; 115(1):9-24. PubMed ID: 18029124
[TBL] [Abstract][Full Text] [Related]
3. IUPHAR - invited review - Ibogaine - A legacy within the current renaissance of psychedelic therapy.
Mash DC
Pharmacol Res; 2023 Apr; 190():106620. PubMed ID: 36907284
[TBL] [Abstract][Full Text] [Related]
4. 100 years of ibogaine: neurochemical and pharmacological actions of a putative anti-addictive drug.
Popik P; Layer RT; Skolnick P
Pharmacol Rev; 1995 Jun; 47(2):235-53. PubMed ID: 7568327
[No Abstract] [Full Text] [Related]
5. DARK Classics in Chemical Neuroscience: Ibogaine.
Wasko MJ; Witt-Enderby PA; Surratt CK
ACS Chem Neurosci; 2018 Oct; 9(10):2475-2483. PubMed ID: 30216039
[TBL] [Abstract][Full Text] [Related]
6. Ibogaine in the treatment of substance dependence.
Brown TK
Curr Drug Abuse Rev; 2013 Mar; 6(1):3-16. PubMed ID: 23627782
[TBL] [Abstract][Full Text] [Related]
7. A systematic literature review of clinical trials and therapeutic applications of ibogaine.
Köck P; Froelich K; Walter M; Lang U; Dürsteler KM
J Subst Abuse Treat; 2022 Jul; 138():108717. PubMed ID: 35012793
[TBL] [Abstract][Full Text] [Related]
8. A non-hallucinogenic psychedelic analogue with therapeutic potential.
Cameron LP; Tombari RJ; Lu J; Pell AJ; Hurley ZQ; Ehinger Y; Vargas MV; McCarroll MN; Taylor JC; Myers-Turnbull D; Liu T; Yaghoobi B; Laskowski LJ; Anderson EI; Zhang G; Viswanathan J; Brown BM; Tjia M; Dunlap LE; Rabow ZT; Fiehn O; Wulff H; McCorvy JD; Lein PJ; Kokel D; Ron D; Peters J; Zuo Y; Olson DE
Nature; 2021 Jan; 589(7842):474-479. PubMed ID: 33299186
[TBL] [Abstract][Full Text] [Related]
9. Fatalities temporally associated with the ingestion of ibogaine.
Alper KR; Stajić M; Gill JR
J Forensic Sci; 2012 Mar; 57(2):398-412. PubMed ID: 22268458
[TBL] [Abstract][Full Text] [Related]
10. A Mixed-Method Analysis of Persisting Effects Associated with Positive Outcomes Following Ibogaine Detoxification.
Davis AK; Renn E; Windham-Herman AM; Polanco M; Barsuglia JP
J Psychoactive Drugs; 2018; 50(4):287-297. PubMed ID: 30020025
[TBL] [Abstract][Full Text] [Related]
11. Underground ibogaine use for the treatment of substance use disorders: A qualitative analysis of subjective experiences.
Rodríguez-Cano BJ; Kohek M; Ona G; Alcázar-Córcoles MÁ; Dos Santos RG; Hallak JEC; Bouso JC
Drug Alcohol Rev; 2023 Feb; 42(2):401-414. PubMed ID: 36456173
[TBL] [Abstract][Full Text] [Related]
12. Addiction research. Ibogaine therapy: a 'vast, uncontrolled experiment'.
Vastag B
Science; 2005 Apr; 308(5720):345-6. PubMed ID: 15831735
[No Abstract] [Full Text] [Related]
13. Phenomenology, Structure, and Dynamic of Psychedelic States.
Preller KH; Vollenweider FX
Curr Top Behav Neurosci; 2018; 36():221-256. PubMed ID: 28025814
[TBL] [Abstract][Full Text] [Related]
14. Treating drug dependence with the aid of ibogaine: a retrospective study.
Schenberg EE; de Castro Comis MA; Chaves BR; da Silveira DX
J Psychopharmacol; 2014 Nov; 28(11):993-1000. PubMed ID: 25271214
[TBL] [Abstract][Full Text] [Related]
15. Psychedelics as medicines for substance abuse rehabilitation: evaluating treatments with LSD, Peyote, Ibogaine and Ayahuasca.
Winkelman M
Curr Drug Abuse Rev; 2014; 7(2):101-16. PubMed ID: 25563446
[TBL] [Abstract][Full Text] [Related]
16. Treatment of acute opioid withdrawal with ibogaine.
Alper KR; Lotsof HS; Frenken GM; Luciano DJ; Bastiaans J
Am J Addict; 1999; 8(3):234-42. PubMed ID: 10506904
[TBL] [Abstract][Full Text] [Related]
17. Ibogaine and Subjective Experience: Transformative States and Psychopharmacotherapy in the Treatment of Opioid Use Disorder.
Brown TK; Noller GE; Denenberg JO
J Psychoactive Drugs; 2019; 51(2):155-165. PubMed ID: 30967101
[TBL] [Abstract][Full Text] [Related]
18. [Psychedelics and quasi-psychedelics in the light of contemporary research: medical cannabis, MDMA, salvinorin A, ibogaine and ayahuasca].
Szabó A; Kazai A; Frecska E; Brys Z
Neuropsychopharmacol Hung; 2015 Sep; 17(3):120-8. PubMed ID: 26485742
[TBL] [Abstract][Full Text] [Related]
19. Changes in Withdrawal and Craving Scores in Participants Undergoing Opioid Detoxification Utilizing Ibogaine.
Malcolm BJ; Polanco M; Barsuglia JP
J Psychoactive Drugs; 2018; 50(3):256-265. PubMed ID: 29608409
[TBL] [Abstract][Full Text] [Related]
20. Psychedelic Treatments for Substance Use Disorder and Substance Misuse: A Mixed Methods Systematic Review.
Sharma R; Batchelor R; Sin J
J Psychoactive Drugs; 2023; 55(5):612-630. PubMed ID: 36933948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
